Blood bank reagent sales will rise through 2036, driven by ABO typing at 51.2% of the test type segment in 2026, supported by increasing clinical adoption and compliance requirements. The market was valued at USD 4.70 billion in 2025 and is expected to be worth USD 8.47 billion by 2036.